Benzinga | Jul 13, 2021 06:18AM EDT

B of A Securities Initiates Coverage On Ambrx Biopharma with Buy Rating, Announces Price Target of $26

B of A Securities initiates coverage on Ambrx Biopharma (NYSE:AMAM) with a Buy rating and announces Price Target of $26.